MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。

MMAE-d₈

CAS No. : 2070009-72-0

MCE 國(guó)際站：MMAE-d₈

產(chǎn)品活性：MMAE-d₈ 是氘代標(biāo)記的 MMAE。MMAE 是一種 tubulin 抑制劑，抑制有絲分裂。

研究領(lǐng)域：Cell Cycle/DNA Damage  |  Cytoskeleton  |  Antibody-drug Conjugate/ADC Related

作用靶點(diǎn)：Microtubule/Tubulin  |  ADC Cytotoxin

In Vitro: Antibody-drug conjugates (ADC) comprise targeting antibodies armed with potent small-molecule payloads. ADCs are generated to target different receptors on the anaplastic large cell lymphoma line L-82, but delivered the same cytotoxic payload (monomethyl auristatin E, MMAE), and the intracellular concentration of released MMAE correlated with in vitro ADC-mediated cytotoxicity independent of target expression or drug:antibody ratios. LC-MS is used to measure the concentration of MMAE in a parallel cohort of L-82 tumors with an identical treatment regimen. Although tumor volume is not different among treatment groups 3 days after dose, the intratumoral MMAE measurement reveals two patterns. First, intratumoral MMAE concentration increases proportionally to the ADC dose, which correspondes to stronger antitumor activity. Second, the intratumoral MMAE concentration obtained from treatment with both cOKT9-vcMMAE and cAC10-vcMMAE is similar at each dose, consistent with the observation that tumor responded similarly to these two ADCs.

In Vivo: Intratumoral MMAE concentrations consistently correlates with the extent of tumor growth inhibition in tumor xenograft models. IHC analysis reveals that nonbinding control-treated tumors consist of both CD30⁺ and CD30^-cells, presumably because they do not kill either CD30⁺ or CD30^- Karpas 299 cells. Only CD30^- cells are found in cAC10-vcMMAF-treated tumors, illustrating that cAC10-vcMMAF eliminates most CD30⁺ cells. Interestingly, the two tumors that relapses from cAC10-vcMMAE treatment are also found to be CD30^- by the end of study, indicating a small fraction of CD30^- cells might have escaped from bystander killing in these two remaining tumors.

相關(guān)產(chǎn)品：Tirbanibulin dihydrochloride  |  Tubulysin IM-3  |  AMXI-5001 hydrochloride  |  Tubulin polymerization-IN-21  |  Dolastatin 10  |  (+)-CBI-CDPI1  |  SB-216  |  MAP4343  |  Duocarmycin GA  |  Tubulin polymerization-IN-8  |  Tubulysin IM-1  |  Maytansinoid B  |  Colchicine-d₃  |  2-Methoxyestradiol-¹³C,d₃  |  Taltobulin  |  Albendazole  |  Duocarmycin DM free base  |  Dideoxy-amanitin  |  Tilavonemab  |  DM4-d₆  |  Camptothecin  |  EGFR-IN-57  |  Epothilone B  |  Epothilone A  |  Maytansinol  |  Cyclopropaneacetamide-Exatecan  |  Docetaxel-d₉  |  Anticancer agent 139  |  N-Me-L-Ala-maytansinol  |  Duocarmycin A

熱門產(chǎn)品線：重組蛋白  |  化合物庫(kù)  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標(biāo)記物  |  寡核苷酸  |  抗體  |  點(diǎn)擊化學(xué)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry